What NAD+ actually does — and why it matters in midlife

You're in your mid-40s, eating well, sleeping reasonably, exercising. And yet your energy doesn't bounce back the way it used to. Recovery takes longer. Your cells are doing more with less — and NAD+ is part of why.

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in virtually every energy-producing process in your cells. It also activates sirtuins — proteins linked to DNA repair, inflammation control, and cellular stress response. By age 40, your NAD+ levels are roughly half what they were at 20. By 60, they've dropped further still. This decline is now understood as one of several mechanisms driving age-related cellular dysfunction.

~50%
drop in NAD+ levels between age 40 and 60 — correlating with declines in energy production, DNA repair capacity, and metabolic function
21+
registered human clinical trials testing NMN as of 2024 — the evidence base is growing, but most trials are short-term and small
500mg
daily NMN dose used in the 2025 postmenopausal women trial showing improved insulin sensitivity — a notable female-specific finding

NMN vs NR: the actual difference

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both precursors to NAD+ — meaning your body converts them into NAD+, rather than using them directly. NMN is one step closer to NAD+ in the conversion pathway, which some researchers argue makes it more efficient. NR has a slightly longer track record in human trials.

Both reliably raise blood NAD+ levels when taken orally. Whether NMN or NR raises intracellular NAD+ (inside cells, where it actually matters) more effectively in humans is still actively debated. The practical difference in human trials is small. If you're choosing between the two, cost and availability matter more than a theoretically superior conversion pathway.

What the human evidence actually shows

A 2024 12-week trial in healthy adults aged 65 to 75 found that 250mg/day NMN significantly improved walking speed and sleep quality versus placebo. A 2025 trial specifically in postmenopausal women found 500mg/day NMN improved insulin sensitivity — a finding with real relevance given the insulin resistance that accelerates after menopause.

Separate research found NMN extended lifespan in female but not male mice — suggesting sex-specific effects that the human trials are only beginning to investigate. The hair thickness finding from a 2025 human trial (where women taking 500mg NMN for 12 weeks saw increased hair diameter) wasn't the primary endpoint, but it's consistent with NAD+'s role in cellular energy and proliferation.

Research Evidence

A 2025 updated review in Food Frontiers comparing NMN and NR concluded both raise NAD+ measurably in blood but that evidence for clinically meaningful outcomes in humans remains heterogeneous. The authors noted that female-specific trials are underrepresented, that the postmenopausal insulin sensitivity data is among the strongest female-specific signals so far, and that longer trials are needed before confident efficacy claims can be made.

The honest limitations

Animal data for NAD+ precursors is genuinely compelling — lifespan extension, metabolic improvement, and cognitive preservation have been shown in multiple species. Human data is catching up but hasn't closed the gap yet. Most human trials are short (8 to 16 weeks), small (20 to 100 participants), and primarily funded by supplement companies. Long-term safety data beyond 12 months is limited.

NAD+ precursors are not regulated as drugs. Supplement quality varies enormously. Third-party testing for purity and dose accuracy matters more here than with most supplements, given the price point.

What to discuss with your doctor

  • ✓
    Mention any cancer history or active cancer treatment. Because NAD+ supports cellular energy and proliferation, some oncologists prefer patients not take NAD+ precursors during active treatment. This is a precautionary position, not confirmed harm — but worth the conversation.
  • ✓
    Check for interactions with metformin or other metabolic medications. Both NAD+ precursors and metformin work on some overlapping pathways — your prescriber should be aware you're taking them together.
  • ✓
    Set a clear evaluation window. If you start NMN or NR, decide upfront what you're measuring (energy, sleep, metabolic markers) and reassess at 12 weeks. This is better than running it indefinitely without an outcome check.
💊

Clinical Note

NAD+ precursors occupy an interesting middle ground: the mechanism is credible, the early human data is encouraging, and the safety profile so far is reassuring. They're not proven longevity drugs yet — but they're not snake oil either. For women in their 40s and 50s with specific concerns about metabolic health or cognitive energy, a time-limited trial at evidence-based doses is reasonable with physician oversight.

Medical Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Sources

  1. An Updated Review on NMN and NR: Mechanisms, Pre-Clinical and Clinical Comparisons. (2025). Food Frontiers (Wiley). Wiley Online Library
  2. The Safety and Antiaging Effects of NMN in Human Clinical Trials: an Update. (2023). Journal of Nutrition and Food Sciences. ScienceDirect
  3. Use of Dietary Supplements NR and NMN to Increase NAD+, Impact Mitochondrial Function, and Improve Metabolic Health. (2024). Nutrients. MDPI
  4. Long-term NMN treatment increases lifespan in female mice. (2024). bioRxiv preprint. bioRxiv
  5. Clinical evidence for the use of NAD+ precursors to slow aging. (2025). Geromedicine. sciexplor.com